A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Trametinib (Primary)
- Indications Brain metastases
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2016 Status changed from suspended to recruiting.